1. Ageev, A.K., 1986. Amyloidosis of the pancreatic
islets and diabetes mellitus. Arkh Patol., 48,
11-15.
2. Beaumont, K., Kenney, M.A., Young, A.A.,
Rink, T.J., 1993. High affinity amylin binding
sites in rat brain. Mol Pharmacol., 44, 493-497.
3. Beeley N.R.A., Prickett K.S., 1996. The amylin,
CGRP and calcitonin family of peptides. Expert
Opin Ther Pat., 6, 555-567.
4. Bhavsar, S.P., Gedulin B.R., Beaumont, K., Rink
T.J., Young A.A., 1995. Inhibition of gastric
emptying and of food intake appear to be independently
controlled in rodents. Proc aust Neurosci.,
21, 460.
5. Bhavsar, S., Watkins, J., Young A., 1997. Comparison
of central and peripheral administration
of amylin on reduction of food intake in rats.
Diabetologia, A302.
6. Bhavsar, S., Watkins, J., Young, A., 1998. Synergy
between amylin and cholecystokinin for inhibition
of food intake in mice. Physiol Behav.,
64, 557-561.
7. Bronsky, J., Prusa, R., 2003. Amylin fasting
plasma levels are decreased in patients with osteoporosis.
Osteoporos Int., 15, 253-247.
8. Castle Arthur L, Kuo C.H., IVY J.L., 1997.
Amylin influences insulin-stimulated glucose
metabolism by two independent mechanism. Endocrinol
Metab., 274, 6-12.
9. Chance, W.T., Balasubramaniam A., Zhang F.S.,
Wimalawansa S.J., Fischer J.E. 1991. Anorexia
following the intrahypothalamic administration
of amylin. Brain Res., 539, 352-354,.
10. Cooper, G.J., Willis, A.C., Clark, A., Turner,
R.C., Sim, R.B., Reid, K.B., 1987. Putrification
and characterization of a peptide from amiloidrich
pancreases of type 2 diabetic patients. P Natl
Acad Sci USA., 84, 8628-8632.
11. Cooper, G.J.S., Leighton, B., Dimitriadis GD,
Parry-Billings M, Kowalchuk, J.M., Howland,
K., Rothbard, J.B., Willis, A.C., Reid K.B., 1988.
Amylin found in amyloid deposits in human type
2 diabetes mellitus may be a hormone that regulates
glycogen metabolism in skeletal muscle. P
Natl Acad Sci USA., 85, 7763-7766.
12. Cooper, M.E., Wookey, P.J., 1997. Amylin-its
role in kidney. Nephrol dial transplant.,12, 8-10.
13. Fineman, M.S., Weyer, C., Maggs D.G., Strobel
S., Kolterman O.G., 2002. The human amylin
analog, pramlintide, reduces postprandial hyperglucagonemia
in patients with type 2 diabetes
mellitus. Horm Metab Res., 34, 504-508.
14. Frank, J.W., Saslow, S.B., Camilleri, M., Thomforde,
G.M., Dinneen, S.F., Rizza, R.A., 1995.
Mechanisms of accelerated gastric emptying of
liquids and hyperglycemia in patients with type II
diabetes mellitus. Gastroenterology, 109, 755-
765.
15. Gedulın, B., Percy, A., Jodka, C., Young, A.,
1997. Studies using neutralizing antibody and the
antagonist AC187 reveal that endogenous amylin
72
inhibits glucagon secretion. Diabetologia, 40,
A300.
16. Gerich, J.E., Schneider, V., Dippe, S.E., 1974.
Characterization of the glucagon response to hypoglycemia
in man. J Clin Endocr Metab., 38,
77-82,
17. Gerich, J.E., 1993. Control of glycaemia. Best
Pract Res Cl En., 7, 551-586.
18. Gren, G.M., Guan, D., Schwartz, J.G., Phillips,
W.T., 1997. Accelerated gastric emptying of glucose
in Zucker type 2 diabetic rats: role in postprandial
hyperglycaemia. Diabetologia, 40, 136-
142.
19. Guidobono F., 1998. Amylin and gastrointestinal
activity. Genetic Pharmacol., 31, 173-177.
20. Hoppener, J.W., Nieuwenhuis, M.G., Vroom,
T.M., Ahren, B.O., Lips, C.J., 2002. Role of islet
amyloid in type 2 diabetes mellitus: consequence
or cause. Mol Cel Endocrinol., 197, 205-212.
21. Koda J.E., Fineman, M., Rink, T.J., Dailey, G.E.,
Muchmore, D.B., Linarelli, L.G., 1992. Amylin
concentrations and glucose control. Lancet, 339,
1179-1180.
22. Kruger, D.F., Gatcomb, P.M., Owen, S.K., 1999.
Clinical implication of amylin and amylin deficiency.
Diabetes, 25, 389-398.
23. Ludvik, B., Kautzky W.A., Prager, R.,
Thomaseth, K., Pacini, G., 1997. Amylin: history
and overview. Diabetic Med., 14, 9-13.
24. Min, S.H., Farr, V.C., Lee, J., Prosser, C.G.,
Cooper, G.J.S., Davis, S.R., 1999. Metabolic effects
of amylin in lactating goats. J Anim Sci., 77,
1241-1248.
25.Moore C.X., Cooper, G.J.S., 1991. Co-secretion
of amylin and insulin from cultured islet betacells:
modulation by nutrient secretagogues, islet
hormones and hypoglycemic agents. Biochem
Bioph Res Co., 179, 1-9.
26. Nakazato, M., Asai, J., Kangawa, K., Matsukura,
S., Matsuo, H., 1989. Establishment of radioimmunoassay
for human islet amyloid polypeptide
and its tissue content and plasma concentration.
Biochem Bioph Res Co., 164, 394-399.
27. Ogawa, A., Harris, V., Mccorkle, S.K., Unger,
R.H., Luskey, K.L., 1990. Amylin secretion from
the rat pancreas and its selective loss after streptozotocin
treatment. J Clin Invest., 85, 973-976.
28. Reda, T.K., Geliebter, A., Pı-Sunyer F.X., 2002.
Amylin, food intake, and obesity. Obes Res., 10,
1087-1091.
29. Silvestre, R.A., Rodriguez-Gallardo, J., Jodka,
C., Parkes, D.G., Pittner, R.A., Young, A.A.,
Marco, J., 2001. Selective amylin inhibition of
the glucagon response to arginine is extrinsic to
the pancreas. Anim J Physiol Endocrinol Metab.,
280, 443-449.
30. Tamura, T., Miyaura, C., Owan, I., Suda, T.,
1992. Mechanism of action of amylin in bone. J
Cell Physiol., 153, 6-14.
31. Unger, R.H., Orci, L., 1977. The role of glucagon
in the endogenous hyperglycemia of diabetes
mellitus. Annu Rev Med., 28, 119-130.
32. Van, R.D., Menard D.P., Fournier, A., St Pierre
S, Quırıon R., 1994. Autoradiographic distribution
and receptor binding profile of [I-125]Bolton
Hunter-rat amylin binding sites in the rat brain. J
Pharmacol Exp Ther., 270, 779-787.
33. Westermark, P., Wilander, E., 1983. Islet amyloid
in type 2 non-insulin-dependent diabetes is
related to insulin. Diabetologia, 24, 342-346.
34. Westermark, P., Wernstedt, C., Wilander, E.,
Sletten, K., 1986. A novel peptide in the calcitonin
gene related peptide family as an amyloid
fibril protein in the endocrine pancreas. Biochem
Biophys Res Commun., 140, 827-831.
35.Wimalawansa, S.J., 1997. Amylin, calcitonin
gene-related peptide, calcitonin, and adrenomedullin:
A peptide superfamily. Crit Rev Neurobiol.,
11, 167-239.
36. Young, A.A., Gedulin, B., Vine, W., Percy, A.,
Rink, T.J., 1995. Gastric emptying is accelerated
in diabetic BB rats and is slowed by subcutaneous
injections of amylin. Diabetologia, 28, 642-
648.
37.Young, A.A., Gedulin, B.R., Rink, T.J., 1996.
Dose-responses for the slowing of gastric emptying
in a rodent model by glucagon like peptide
(7-36)NH2, amylin, cholecystokinin, and other
possible regulators of nutrient uptake. Metabolism,
45, 1-3.
38.Young, A.A., Vine, W., Gedulin, B.R., 1996
Preclinical pharmacology of pramlintide in the
rat: comparisons with human and rat amylin.
Drug Develop Res., 37, 231-248.
39.Young, A., 1997. Amylin's physiology and its
role in diabetes. Curr Opin Endocrinol Diab.,
282-290.
40.Young, A., 1997. Role of amylin in nutrient intake-
animal studies. Diabetic Med., 14, 14-18.
41.Young, A., 2005. Historical background. Adv
Pharmacol., 52, 1-18.
Thank you for copying data from http://www.arastirmax.com
